Wednesday, October 27, 2010

Another stroke prevention drug

Atrial fibrillation is a common cause of stroke, as mentioned before. The U.S. Food and Drug Administration just approved a new drug for stroke prevention for those patients. Stroke is the third leading cause of death in the United States and is the leading cause of permanent disability.

FDA approves Pradaxa to prevent stroke in people with atrial fibrillation

The U.S. Food and Drug Administration today approved Pradaxa capsules (dabigatran etexilate) for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).

Atrial fibrillation, which affects more than 2 million Americans, involves very fast and uncoordinated contractions of the heart’s two upper heart chambers (atria) and is one of the most common types of abnormal heart rhythm.

“People with atrial fibrillation are at a higher risk of developing blood clots, which can cause a disabling stroke if the clots travel to the brain,” said Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products in the FDA’s Center for Drug Evaluation and Research.
 (Image from National Institutes of Health)

No comments: